Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie fazy 2 Ianalumabu (VAY736) u pacjentów z pierwotną małopłytkowością immunologiczną (ITP) wcześniej leczonych co najmniej dwiema liniami terapii

19 października 2026 zaktualizowane przez: Novartis Pharmaceuticals

Badanie fazy 2 oceniające skuteczność i bezpieczeństwo Ianalumabu (VAY736) u pacjentów z pierwotną małopłytkowością immunologiczną (ITP) wcześniej leczonych co najmniej kortykosteroidem i agonistą receptora trombopoetyny (TPO-RA)

The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.

Przegląd badań

Status

Aktywny, nie rekrutujący

Interwencja / Leczenie

Szczegółowy opis

This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count <30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.

The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

41

Faza

  • Faza 2

Rozszerzony dostęp

Do dyspozycji poza badaniem klinicznym. Zobacz rozwinięty rekord dostępu.

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • CABA, Argentyna, C1181ACH
        • Novartis Investigative Site
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Novartis Investigative Site
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Novartis Investigative Site
      • Beijing, Chiny, 100730
        • Novartis Investigative Site
      • Jinan, Chiny, 250012
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Chiny, 430022
        • Novartis Investigative Site
      • Toulouse, Francja, 31059
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Hiszpania, 08003
        • Novartis Investigative Site
      • Seoul, Korea Południowa, 06591
        • Novartis Investigative Site
      • Johor Bahru, Malezja, 80100
        • Novartis Investigative Site
      • Giessen, Niemcy, 35392
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Niemcy, 01307
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, Niemcy, 07740
        • Novartis Investigative Site
      • Katowice, Polska, 40-519
        • Novartis Investigative Site
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Beth Israel Deaconess Med Center
      • Izmir, Turcja (Türkiye), 35100
        • Novartis Investigative Site
      • Kocaeli, Turcja (Türkiye), 41380
        • Novartis Investigative Site
    • Efeler
      • Aydin, Efeler, Turcja (Türkiye), 09100
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turcja (Türkiye), 34098
        • Novartis Investigative Site
    • Merkez
      • Edirne, Merkez, Turcja (Türkiye), 22030
        • Novartis Investigative Site
    • TO
      • Torino, TO, Włochy, 10126
        • Novartis Investigative Site
      • Glasgow, Zjednoczone Królestwo, G31 2ER
        • Novartis Investigative Site
      • London, Zjednoczone Królestwo, W12 0HS
        • Novartis Investigative Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 100 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Signed informed consent obtained prior to participation in the study.

  • Male or female participants aged 18 years and older on the day of signing informed consent.

  • Confirmed diagnosis of primary ITP.

    • Prior treatment with at least a corticosteroid (±IVIG) and a TPO-RA:
    • Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
    • Prior response to IVIG/anti-D or a corticosteroid (platelet count ≥50 G/L) that was not maintained.
  • At last ITP treatment, loss of response, insufficient response, no response or intolerance.

  • Platelet count <30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value <30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.

Key exclusion criteria:

  • Diagnosis of secondary thrombocytopenia.

  • Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.

  • Participants with the following conditions at screening:

    • Neutrophils <1000/mm3.
    • Immunoglobulin G (IgG) <5 g/L
  • Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.

  • Immunosuppressant drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.

  • Prior splenectomy.

Other protocol-defined inclusion/exclusion criteria may apply.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Single-arm

All eligible participants will receive ianalumab at the same dose.

Intravenous infusion, prepared from concentrate solution

Inne nazwy:
  • VAY736

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Confirmed response
Ramy czasowe: Between Week 1 Day 1 and Week 25 Day 1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New immune thrombocytopenia (ITP) treatment before reaching a confirmed response.
Between Week 1 Day 1 and Week 25 Day 1

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Time to confirmed response
Ramy czasowe: From Week 1 Day 1 to Week 25 Day 1

Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint.

From Week 1 Day 1 to Week 25 Day 1
Duration of confirmed response
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Complete Response rate at each timepoint
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Response rate at each timepoint
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Stable response at 6 months
Ramy czasowe: At 6 months

Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 6 months
Stable response at 1 year
Ramy czasowe: At 1 year

Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 1 year
Bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Number of participants who received rescue treatment
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants who received rescue treatment
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the frequency of CD19+ B-cell counts
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline frequency of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the absolute number of CD19+ B-cell counts
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in immunoglobulins
Ramy czasowe: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Ramy czasowe: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Ramy czasowe: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Ianalumab serum concentrations over time
Ramy czasowe: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK: AUC concentrations over time
Ramy czasowe: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Cmax
Ramy czasowe: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Tmax
Ramy czasowe: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Confirmed response (CR) in the second course
Ramy czasowe: Second course Week 1 Day1 to second course Week 25 Day1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New ITP treatment before reaching a confirmed response.
Second course Week 1 Day1 to second course Week 25 Day1
Time to confirmed response in the second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

two (or more) platelet assessments meeting the criteria of a confirmed response.

Second course Week 1 Day 1 to second course Week 25 Day 1
Duration of confirmed response in the second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
Second course Week 1 Day 1 to second course Week 25 Day 1
Response in the second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Complete Response in the second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Number of Participants who received rescue treatment after second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants who received rescue treatment after receiving second course
Ramy czasowe: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course
Ramy czasowe: Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
Change from start of second course in immunoglobulins
Ramy czasowe: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course in the absolute number of CD19+ B-cell counts
Ramy czasowe: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course to end of study in the absolute number of CD19+ B-cell counts
Ramy czasowe: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Ramy czasowe: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Ianalumab serum concentrations over time in the second course
Ramy czasowe: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Dyrektor Studium: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

16 sierpnia 2023

Zakończenie podstawowe (Rzeczywisty)

5 lutego 2025

Ukończenie studiów (Szacowany)

19 marca 2029

Daty rejestracji na studia

Pierwszy przesłany

15 maja 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 maja 2023

Pierwszy wysłany (Rzeczywisty)

2 czerwca 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

19 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj